Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daré Bioscience Inc (DARE)
NASDAQ:DARE
Daré Bioscience (DARE) Stock Price & Analysis
1,758 Followers
DARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.27 - $1.05
Previous Close$0.36
Volume909.18K
Average Volume (3M)711.91K
Market Cap
$36.39M
Enterprise Value$22.69M
Total Cash (Recent Filing)$13.90M
Total Debt (Recent Filing)$195.00K
Price to Earnings (P/E)-1.2
Beta1.20
Next Earnings
Aug 08, 2024Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding101,092,900
10 Day Avg. Volume506,550
30 Day Avg. Volume711,910
Standard Deviation0.22
R-Squared0.10
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-13.84
Price to Sales (P/S)3.64
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue22.69
Enterprise Value/Gross Profit2.27
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$3.67Price Target Upside744.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Daré Bioscience News
Bulls Say, Bears Say
Bulls Say
Financial StrategyDaré bolsters its financial position with $22M in gross proceeds from a royalty monetization, ensuring continued support for its Phase 3 studies.
Product DevelopmentDaré's novel product, Ovaprene, could revolutionize contraception as the first monthly, hormone-free option, pending approval.
Strategic PartnershipsThe company benefits from strong partnership support as evidenced by the collaboration with the NIH and Bayer for the Ovaprene P3 study.
Bears Say
Capital RisksRisks include financial needs greater than the company's current cash balance and the likelihood of needing to raise additional capital.
Financial PerformanceDaré recorded total revenue of $9.3K from license, milestone and royalty income, below the street consensus of $0.5M.
Product PerformanceSildenafil Cream did not achieve statistical significance for the co-primary endpoints in the exploratory study.
---
Ownership Overview
23.87%
Insiders
4.33% Mutual Funds
3.64% Other Institutional Investors
68.17% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DARE FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was $0.27 and its highest was $1.05 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Currently, no data Available
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is Aug 08, 2024 which is in 84 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on May 14, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.06 by -$0.01.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is $0.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 101,092,900 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.06. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DARE
---
Daré Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.67 (744.07% Upside)
$3.67 (744.07% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-57.15%
Trailing 12-Months
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert, and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.
---
DARE Earnings Call
Q1 2024
0:00 / 0:00
---
DARE Stock 12 Month Forecast
Average Price Target
$3.67
▲(744.07% Upside)
Technical Analysis
Agile Therapeutics
―
Evofem Biosciences
―
Aileron Therapeutics
―
Mersana Therapeutics
―
Best Analysts Covering DARE
1 Year
1 Year Success Rate
7/23 ratings generated profit
1 Year Average Return
-4.03%
reiterated a buy rating 9 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 30.43% of your transactions generating a profit, with an average return of -4.03% per trade.
---